Furthermore, patients with low NRP1 expression who had a diagnosis of primary or metastatic melanoma had a significantly better disease-specific 5-year survival compared with patients with high NRP1 expression (P=0.02 for primary and metastatic groups; Fig. 4A, right column). The gene discussed is NRP1; the disease is metastatic melanoma.